Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) issued its earnings results on Tuesday. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. Dianthus Therapeutics has a 1-year low of $18.08 and a 1-year high of $114.55. Dianthus Therapeutics Company Profile(Get Free Report)Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. Further ReadingReceive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.